Previous 10 | Next 10 |
2023-06-21 11:02:52 ET The leading drug industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the U.S. government on Wednesday, challenging the drug pricing negotiations introduced by the recently-enacted Inflation Reduction Act. The N...
2023-06-17 06:10:00 ET Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly. Three Motley Fool contributors think they've identified stocks that are great candidates to buy on the dip right now. Here's why th...
2023-06-15 13:17:52 ET Summary CVS has seen its shares decline to a pretty low price. The valuation is very undemanding. The yield is high, and the long-term outlook is solid. Article Thesis CVS Health Corporation ( CVS ) has seen its shares slump on comments fro...
2023-06-15 10:45:16 ET Summary TEVA's new plan will see it shift its focus and resources to innovative medicines like Austedo that enjoy higher margins than generics. Austedo has been performing well historically, with plans to grow its sales to $2.5 billion in 2027 from the $1.2 ...
Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly reduced migraine days and depression symptoms in patients with migraine and major depressive...
2023-06-13 07:54:32 ET Teva Pharmaceutical Industries ( NYSE: TEVA ) said it has agreed to pay $1.41M to settle the State of Kentucky's price-fixing claims against the company. The Israeli drugmaker said the settlement, which was reached with Kentucky's attorney general's office...
2023-06-12 17:22:16 ET Teva Pharmaceutical Industries ( NYSE: TEVA ) said it has agreed to pay $1.41B to settle the State of Kentucky's price-fixing claims against the company. The Israeli drugmaker said the settlement, which was reached with Kentucky's attorney general's office...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Kentucky to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $1.407 million...
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech c...
2023-06-09 15:17:22 ET The US Food and Drug Administration is reportedly seeking temporary suppliers to help ease US shortages of methotrexate, a drug that is commonly used to treat cancer and autoimmune disorders such as rheumatoid arthritis. An FDA spokesperson told Reuters that the a...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...